INVESTING IN OUR STORY

OUR STORY IS THE FUTURE

Our treatments have the potential to fuel a new era of dermatology.

Cassiopea S.p.A. is listed on the Swiss stock exchange (ticker: SKIN) with the vision of building a leading, fully integrated dermatology company. Cassiopea, Inc., our United States subsidiary, was created with the mission to commercialize Cassiopea’s products in the United States.

SHARE INFORMATION

Italian Financial Transactions Tax
The Italian Law n. 228 (published in the Gazzetta Ufficiale No. 302 on December 29, 2012) stipulates that a financial transaction tax amounting to 0.22% of the transaction value is to be levied on all financial transactions for listed securities.

Article 1, comma 491, stipulates that this Financial Transaction Tax is not applicable on securities issued by corporations that have a market capitalization of less than EUR 500 million as calculated on the average market capitalization in the month of November preceding the transaction.

Issued shares
10,000,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized.

Additionally approved shares
1,000,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized, to be issued with the exclusion of subscription rights according to section 2441, 4° subsection Italian Civil Code,  (resolution valid until 5 April 2023).
3,000,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized, to be issued according to section 2443 Italian Civil Code (resolution valid until 18 March 2024).

500,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized, to be issued according to section 2443 Italian Civil Code to cover the company’s obligations out of its Stock Option Program (“SOP”) (resolution valid until 18 March 2024).

SIX
Cassiopea
39.00
+0.00(+0%) CHF
Volume
5252
Market Cap (Mn)
428.00 CHF
Day High
40.00
Day Low
39.00
Detailed Share information

OWNERSHIP STRUCTURE

Cosmo Pharmaceuticals NV 45.1%
Cosmo Holding Sarl 7.5%
Herz/Logistable Group 4.1%
LB Swiss 3.6%

KEY FINANCIAL DATA

EUR1,000 2018 2017 2016 2015 2014
Income statements
Revenues - - - - -
Other income 916 3,820 5,883 - -
Cost of sale - - - - -
R&D costs (12,240) (13,061) (14,310) (7,597) (3,858)
SG&A costs (1,890) (1,484) (2,026) (760) (61)
Operating result (13,214) (10,725) (10,453) (8,357) (3,919)
Profit (loss) before taxes (12,656) (13,656) (9,496) (6,451) (3,883)
Profit (loss) after taxes (12,656) (13,656) (9,496) (6,451) (2,776)
Statement of financial position
Non-current assets 9,760 9,104 5,941 232 1,463
Cash and cash equivalents 4,609 17,598 33,656 48,113 840
Other current assets 2,171 1,767 2,328 1,491 1,520
Liabilities 2,028 2,115 2,776 2,655 197
Equity attributable to owners of the Company 14,512 26,354 39,149 47,181 3,626
Equity ratio (in %) 88% 93% 93% 95% 95%
Shares
Weighted average number of shares 10,000,000 10,000,000 10,000,000 5,795,890 5,795,890
Earnings (loss) per share (in EUR) (1.266) (1.366) (0.950) (1.113) (0.479)

FINANCIAL PUBLICATIONS & PRESENTATIONS

DATE TITLE DOCUMENT
November 13-20, 2019 Credit Suisse & Jefferies Presentation
July 19, 2019 2019 Half Year Report
July 18, 2019 2019 Half Year Presentation
February 8, 2019 2018 Annual Report
DATE TITLE DOCUMENT
July 18, 2018 2018 Half Year Report
February 28, 2018 2017 Annual Report
DATE TITLE DOCUMENT
July 27, 2017 2017 Half Year Report
February 24, 2017 2016 Annual Report
DATE TITLE DOCUMENT
February 24, 2016 2015 Annual Report
DATE TITLE DOCUMENT
September 24, 2015 2015 Half Year Report
DATE
November 13-20, 2019
TITLE
Annual Report 2018
DATE
July 19, 2019
TITLE
Annual Report 2018
DATE
July 18, 2019
TITLE
Annual Report 2018
DATE
February 8, 2019
TITLE
Annual Report 2018
DATE
July 18, 2018
TITLE
Annual Report 2018
DATE
February 28, 2018
TITLE
Annual Report 2018
DATE
July 27, 2017
TITLE
Annual Report 2018
DATE
February 24, 2017
TITLE
Annual Report 2018
DATE
February 24, 2016
TITLE
Annual Report 2018
DATE
September 24, 2015
TITLE
Annual Report 2018

FINANCIAL CALENDAR

DATE TITLE ADD TO CALENDAR
Mar 03 - Mar 04 2020 Credit Suisse Global Health Care Conference, London
Mar 18 2020 Financial Statements
Apr 06 - Apr 07 2020 HC Wainwright Global Healthcare Conference
Apr 23 2020 Shareholders meeting, Lainate
Jun 02 - Jun 04 2020 Jefferies Global Healthcare Conference, NY
Sep 23 - Sep 24 2020 Investora, Zurich
Nov 18 - Nov 20 2020 Credit Suisse Mid Cap Conference, Zurich

LATEST NEWS

November 13, 2019
chevron right icon

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

November 8, 2019
chevron right icon

Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

August 20, 2019
chevron right icon

Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.

Winlevi is under investigation in the United States for the treatment of acne, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone cream 1% is not FDA-approved.